Sumner M.J.,Ashland Performance Materials
Plastics Engineering | Year: 2015
New sheet molding compounds met density, surface quality, and mechanical property goals for lightweight, next-generation automotive body panels and closures through extensive research. The initial experiments involved simply replacing the unsaturated polyester (UPR) in the Arotran 720/722 system with a series of six different vinyl ester resins. These resins were a mixture of commercial and experimental vinyl esters. From this initial screening, none of the experimental formulas produced a Class A surface. Two formulas were close enough in range such that an improvement in shrink control in those systems would yield a Class A surface.
Johnson R.A.,Ashland Performance Materials
Web Coating and Handling Conference 2013 | Year: 2013
Two-component solventless, 100% reactive urethane laminating adhesives are used in high speed converting of film-to-film laminations for food, industrial goods and lawn and garden packaging. There are two general classes of solvent-free laminating adhesives: (1) aromatic isocyanate-based and (2) aliphatic isocyanate-based. Generally, aromatic isocyanate based adhesives cost less, but are typically used in non-food and low-to-medium performing food packaging due to migration requirements. Aromatic solvent-free adhesives have readily replaced solvent-based aromatic adhesives in the low-to-medium food packaging applications because of lower applied cost, very good adhesion performance and the assumption aromatic solventless adhesives will meet the migration requirements for these applications. In applications requiring extremely low migration, aliphatic isocyanate-based adhesives have been successful, but cost significantly more and have not met the same adhesion performance level as aromatic solvent-free adhesives. With new analytical equipment and new methodology to detect migrants at sub part per billion level, there is an increasingly high challenge for suppliers into flexible packaging to meet the demands of suitability for use in fatty, aqeous and alcoholic containing foods; especially for elevated temperature applications such as hot-fill, microwavable, and boil-in-bag. Ashland has developed new ultra low migration technology in two-component, solventfree aromatic urethane laminating adhesives. This new technology provides a lower cost, more environmentally sustainable solution for converters to use for all types of food packaging. Copyright© (2013) by the Association of International Metallizers, Coaters and Laminators.
News Article | September 8, 2008
British Biotech Antisoma Sees Buyout of Xanthus as Beginning of U.S. Commercial Hub in Cambridge, MA Glyn Edwards, CEO of British biotech firm Antisoma, has found just the tonic for both the particularly gloomy weather in London this year and the business risk his company once faced with only one experimental drug close to market approval: Cambridge, MA, drug developer Xanthus Pharmaceuticals. Xanthus, which Antisoma (LON:ASM) acquired in May for $52.2 million in Antisoma stock, provides Antisoma with two more prime commercial drug candidates. Now Edwards—who notes that one perk of the deal is the sunnier weather he enjoys during regular trips to this side of the Atlantic—plans to begin building a commercial team in Cambridge with a first hire later this year, in anticipation of hoped-for approvals of his firm’s anti-cancer treatments over the next several years. He also talked to me about how Antisoma first walked away from merger talks with Xanthus in 2007, but returned to the negotiating table after privately held Xanthus later reached two key milestones. “Obviously, drug-development is a risky business; you can’t predict with absolute certainty what the results of these trials will be,” Edwards says, “but we have a high probability that at least one of these drugs is going to get through its Phase III.” When M&A talks began between Antisoma and Xanthus last year, Antisoma’s only late-stage commercial drug prospect was its lead product candidate, called ASA404, which is in Phase III clinical trials to treat non-small cell lung cancer. (Swiss drug giant Novartis (NYSE:NVS) has licensed exclusive rights to ASA404, but Antisoma retains the option to become Novartis’ U.S. commercialization partner for the drug.) Now, with Xanthus’ pipeline in the Antisoma fold, the British biotech has added AS1413 (formerly Xanafide), which is in Phase III trials to treat secondary acute myeloid leukemia (AML), and oral fludarabine, which is pending FDA review and which could be approved by early 2009 as a secondary treatment for chronic lymphocytic leukemia. (For you science-minded folks, Antisoma gives details on the mechanisms of action of each drug here.) Xanthus also gave Antisoma a ready-made drug development organization in the U.S., with internal expertise to manage the late-stage clinical trials and earlier-stage work on drugs in its pipeline. Antisoma has retained most Xanthus employees. For example, Mike Boss, who was chief business officer of Xanthus prior to the acquisition, has become general manager of the firm’s autoimmune program. Yet Richard Dean, former CEO of Xanthus, left the company shortly after the buyout. Antisoma has also folded an operation it launched in Princeton, NJ, last year into the 30-person Cambridge office, Edwards says. Though most of the firm’s workers, about 90 employees, are now housed in its London office, the CEO says he foresees the Cambridge outpost employing an equal number of people within the next several years. (Novartis projects potential approval of AS1413 in the U.S. by 2011, he says, and Antisoma would like to build a sales force here by then to handle its part of the joint-commercial effort for that drug.) Though I hadn’t heard or read this before, Xanthus had been running a dual effort last year to consider whether to seek an initial public offering or find a buyer of the firm. Antisoma, searching at the time for a deal to bring it more late-stage product candidates, entered initial buyout talks with Xanthus yet walked away because the FDA had not yet accepted the New Drug Application for oral fludarabine or cleared secondary AML as an indication for the Phase III trial of ASA1413. But the regulatory agency later accepted both the NDA and the secondary AML indication. “So we got back in touch with (Xanthus) once we saw that both these events had happened,” Edwards says, “and we said, ‘You were right and we were wrong. How about getting married?'” As Antisoma details in its announcement of the May 2008 acquisition, Xanthus shareholders—including such Boston-area venture capital firms as Oxford Bioscience Partners, HealthCare Ventures, and Still River Funds—exchanged their Xanthus shares for Antisoma stock. Michael Lytton, a general partner at Oxford who represented the VC firm in the deal, says that Xanthus investors decided after testing the IPO and M&A waters that they could get the best returns on their investments by converting theirs shares into stock in a consolidator in the field of oncology, which turned out to be Antisoma. Lytton says his firm maintains a 4-5 percent stake in Antisoma, and plans to sell its stock once its price (which was 43 cents on September 4) triples in value. “We see ourselves being shareholders for a couple of years,” Lytton says, “through the point where Antisoma becomes a commercial organization.”
Stevens M.,Ashland Performance Materials |
Graham J.,Ashland Performance Materials |
Mizzi F.,Nuplex Composites
Annual Conference of the Australasian Corrosion Association 2012 | Year: 2012
Mineral processing and chemical processing industries often employ chemicals that are very corrosive to materials of construction such as steel and concrete commonly found in tanks, process vessels and piping. These construction materials need additional protection from corrosion. Past solutions have included rubber linings. Unfortunately, rubber linings are difficult to apply and require a great deal of maintenance over the life of the equipment. Fiber reinforced (FRP) epoxy vinyl ester resin linings have demonstrated excellent chemical resistance and require minimal maintenance over the life of the equipment. Choosing the proper resin for the corrosive environment is critical to liner performance. The method for determining the proper resin will be described in the paper and a comparison of performance will be shown using ASTM C581 test data. Proper construction of the FRP liner is equally important to insure a successful application. These linings can additionally provide outstanding abrasion resistance when formulated properly with additives such as silicon carbide. The affect of several potential abrasion resistant additives will be described with test data showing how each material improves the abrasion resistance in the FRP liner. Examples of equipment constructed with these epoxy vinyl ester linings such as mixer settlers, storage tanks, process vessels, etc. will be discussed. Copyright © (2012) by the Australasian Corrosion Association.
Stevens M.,Ashland Performance Materials |
Coutelen P.,Ashland Performance Materials
ACS Symposium Series | Year: 2012
Fiber-reinforced polymers (FRP) have been used widely in building, construction and mass transit applications in many parts of the world. Although some efforts towards the harmonization of fire performance standards are taking place (like EN45545 in the European train industry) most countries continue to have their own requirements to qualify materials for specific applications. As the economy becomes more global, it would be helpful for composite fabricators and end users to predict how materials perform in the different tests. A study was undertaken to test 10 different materials from the United States and Europe to see how they perform in a range of North American and European fire performance tests. The tests studied were UL 94, ASTM E162, ASTM E84, ASTM E662, ASTM E1354, IMO A653, NFP 92501, NFP 16-101, and EN 13823. The results will be discussed. Although it was found that fire performance is generally dependant upon the resin system and the type of fire retardant used, the fire performance in a given test was seldom indicative of a material's performance in another procedure. © 2012 American Chemical Society.